Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)

CUSIP: 87650L103

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock
Total 13F shares
46,131,357
Total 13F value
$1,868,819,935
Holder snapshot 6 visible 7 signals
Share change
+2,514,921
Put/Call ratio
0%
SEC-reported price per share
$40.51
Number of holders
204
Value change
+$92,954,236
Number of buys
130
Open additional details 1 more signal available
Number of sells
78
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
42,282,321

Security key

87650L103

Report period

Q2 2025

Institutions

204

Top holders

10

TARS full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 Tarsus Pharmaceuticals, Inc. SEC filings Tarsus Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of TARS - Tarsus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RTW INVESTMENTS, LP
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F 13D/G 3/4/5 Lead comparable stake: 8.1% 13D/G row: RTW INVESTMENTS, LP Showing 1-6 of 15 holder rows.

Quick read

RTW INVESTMENTS, LP leads the comparable SEC ownership view at 8.1%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RTW INVESTMENTS, LP's linked filing trail.
Comparable ownership Top 5
RTW INVESTMENTS, LP 8.1%
BlackRock, Inc. 7.4%
Cowen Financial Products LLC 4.9%
MORGAN STANLEY 4.7%
Paradigm Biocapital Advisors LP 6.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RTW INVESTMENTS, LP
13F 13D/G 3/4/5
Company · 10%+ Owner
13F 13D/G 3/4/5
8.1%
from 13D/G
$170,344,564
3,316,032 shares
 — 31 Mar 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
7.4%
from 13D/G
$162,007,007
3,153,728 shares
 — 31 Mar 2025
Cowen Financial Products LLC
13D/G
13D/G
4.9%
$94,926,816
1,909,228 shares
 $0 31 Dec 2024
MORGAN STANLEY
13F 13D/G
Company
13F 13D/G
4.7%
from 13D/G
$103,396,399
2,012,777 shares
 — 31 Mar 2025
Paradigm Biocapital Advisors LP
13F
Company
13F
6.2%
$134,085,820
2,610,197 shares
 — 31 Mar 2025
JENNISON ASSOCIATES LLC
13F
Company
13F
5.9%
$128,046,917
2,492,640 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
204
Shares
46,131,357
Rows available
204
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
191
Q2 2025 holders
204
Holder diff
13
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .